Document is current

Article History

Received: 28 September 2024

Accepted: 7 April 2025

First Online: 25 April 2025

Ethics

: The study was conducted in accordance with Good Clinical Practice guidelines and the World Medical Association Declaration of Helsinki. Patient anonymity was maintained by de-identifying clinical and genomic data before analysis. All patients provided written informed consent. The study protocol was approved by independent ethics committees at each participating institution (Institutional Review Board from Hospital Clinic Barcelona and Hospital Universitario 12 de Octubre).

: R.S.-B. reports advisory/consulting/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, Eisai, GlaxoSmithKline, Reveal Genomics, and Gilead; travel expenses from Pfizer, AstraZeneca, Gilead, Novartis, and Roche. O.M.S. reports advisory/consulting fees from Reveal Genomics, Roche, and AstraZeneca, lecture fees from Daiichi Sankyo, Novartis, Pfizer, and Eisai, and travel expenses from Gilead and Novartis. E.S. declares personal fees for educational events and/or material from Novartis, Pfizer, Eisai, and Daiichi Sankyo; advisory fees from Pfizer and Seagen; and travel/accommodation expenses from Gilead, Daiichi Sankyo, Novartis, and Lilly. P.T. reports advisory and consulting fees from AstraZeneca, Daiichi-Sankyo, Adamed, Novartis, Pfizer, Lilly, Esteve, Gilead, Roche, and Reveal Genomics. T.P. reports advisory and consulting fees or speaker honoraria from Novartis, Astra Zeneca, Lilly, Pfizer, Veracyte, Gilead, and Roche, and support for attending meetings and/or travel from Gilead. A.M. reports advisory and consulting fees from AstraZeneca, Clovis (ended), GSK, MSD, PharmaMar, Pharma&, Immunogen. F.B-M. reports part-time employment from Reveal Genomics and has patents filed: PCT/EP2022/086493, PCT/EP2023/060810, EP23382703, and EP23383369. E.C. reports advisory/consulting/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, and Gilead; travel expenses from Pfizer, AstraZeneca, MSD, Novartis, and Roche. A.P. reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, Ona Therapeutics, and Peptomyc, lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; patents filed PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703, and EP23383369; editor of NPJ Breast Cancer journal. The remaining authors declare no competing interests.